Role of PPAR-δ in the development of zymosan-induced multiple organ failure: An experiment mice study

Journal of Inflammation

Volumn 7, Issue , 2010, Pages

  Galuppo, Maria ^a   Di Paola, Rosanna ^b   Mazzon, Emanuela ^b   Genovese, Tiziana ^a,b   Crisafulli, Concetta ^a   Paterniti, Irene ^a   Cuzzocrea, Elisabetta ^b   Bramanti, Placido ^b   Kapoor, Amar ^c   Thiemermann, Christoph ^c   Cuzzocrea, Salvatore ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; DIMETHYL SULFOXIDE; FAS LIGAND; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; MYELOPEROXIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN BAX; PROTEIN BCL 2; TUMOR NECROSIS FACTOR; ZYMOSAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINE; LUNG; MALE; MOUSE; MULTIPLE ORGAN FAILURE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PANCREAS; PERITONEUM EXUDATE; PROTEIN EXPRESSION;

MUS;

EID: 77949479336     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-7-12     Document Type: Article

References (52)

1. Zymosan-induced generalized inflammation: experimental studies into mechanisms leading to multiple organ dysfunction syndrome. TJ Volman T Hendriks RJ Goris, Shock (Augusta, Ga) 2005 23 4 291 297
2. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. A Tenenbaum M Motro EZ Fisman, Cardiovasc Diabetol 2005 4 14
3. Peroxisome proliferator-activated receptor beta/delta activation improves angiotensin II-induced cardiac hypertrophy in vitro. L Sheng P Ye YX Liu CG Han ZY Zhang, Clin Exp Hypertens 2008 30 2 109 119
4. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. O Braissant F Foufelle C Scotto M Dauca W Wahli, Endocrinology 1996 137 1 354 366
5. Cloning of a protein that mediates transcriptional effects of fatty acids in preadipocytes. Homology to peroxisome proliferator-activated receptors. EZ Amri F Bonino G Ailhaud NA Abumrad PA Grimaldi, J Biol Chem 1995 270 5 2367 2371
6. Activation of gene transcription by prostacyclin analogues is mediated by the peroxisome-proliferators-activated receptor (PPAR). R Hertz I Berman D Keppler J Bar-Tana, Eur J Biochem 1996 235 1-2 242 247
7. PPARs: therapeutic targets for metabolic disease. JP Berger TE Akiyama PT Meinke, Trends Pharmacol Sci 2005 26 5 244 251
8. Be fit or be sick: peroxisome proliferator-activated receptors are down the road. B Desvergne L Michalik W Wahli, Mol Endocrinol 2004 18 6 1321 1332
9. PPAR delta: an uncompletely known nuclear receptor. A Fredenrich PA Grimaldi, Diabetes Metab 2005 31 1 23 27
10. Ethyl pyruvate reduces the development of zymosan-induced generalized inflammation in mice. R Di Paola E Mazzon T Genovese C Crisafulli P Bramanti R Caminiti E Esposito MP Fink S Cuzzocrea, Crit Care Med 2009 37 1 270 282
11. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992 20 6 864 874
12. Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle? AE Baue R Durham E Faist, Shock 1998 10 2 79 89
13. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. JC Marshall, Crit Care Med 2001 29 7 Suppl 99 106
14. Does selective decontamination of the gastrointestinal tract prevent multiple organ failure? An experimental study. RJ Goris IP van Bebber RM Mollen JP Koopman, Arch Surg 1991 126 5 561 565
15. Comparison between lung and liver lipid peroxidation and mortality after zymosan peritonitis in the rat. R Demling U Nayak K Ikegami C LaLonde, Shock 1994 2 3 222 227
16. Neutrophil function and lipid peroxidation in a rat model of multiple organ failure. IP van Bebber WK Boekholz RJ Goris PH Schillings HP Dinges S Bahrami H Redl G Schlag, J Surg Res 1989 47 6 471 475
17. Tumour necrosis factor alpha (TNF-alpha) and interleukin 6 in a zymosan-induced shock model. EJ von Asmuth JG Maessen CJ van der Linden WA Buurman, Scand J Immunol 1990 32 4 313 319
18. Tumor necrosis factor mediates zymosan-induced increase in glucose flux and insulin resistance. F Petit GJ Bagby CH Lang, Am J Physiol 1995 268 2 Pt 1 219 228
19. Platelet-activating factor and the vascular effects of zymosan in rats. J Damas G Remacle-Volon V Bourdon, Eur J Pharmacol 1993 231 2 231 236
20. Protein malnutrition predisposes to inflammatory-induced gut-origin septic states. EA Deitch WJ Ma L Ma RD Berg RD Specian, Ann Surg 1990 211 5 560 567
21. Role of the gut lymphatic system in multiple organ failure. EA Deitch, Curr Opin Crit Care 2001 7 2 92 98
22. Organ damage in zymosan-induced multiple organ dysfunction syndrome in mice is not mediated by inducible nitric oxide synthase. TJ Volman RJ Goris M van der Jagt FA van de Loo T Hendriks, Crit Care Med 2002 30 7 1553 1559
23. Role of interleukin-6 in a non-septic shock model induced by zymosan. S Cuzzocrea G de Sarro G Costantino E Mazzon R Laura E Ciriaco A de Sarro AP Caputi, Eur Cytokine Netw 1999 10 2 191 203
24. Inducible nitric oxide synthase knockout mice exhibit resistance to the multiple organ failure induced by zymosan. S Cuzzocrea E Mazzon L Dugo A Barbera T Centorrino A Ciccolo MT Fonti AP Caputi, Shock 2001 16 1 51 58
25. Erythropoietin reduces the development of experimental inflammatory bowel disease. S Cuzzocrea E Mazzon R Di Paola NS Patel T Genovese C Muia A De Sarro C Thiemermann, J Pharmacol Exp Ther 2004 311 3 1272 1280
26. Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. M Abdelrahman EJ Sharples MC McDonald M Collin NS Patel MM Yaqoob C Thiemermann, Shock 2004 22 1 63 69
27. Activated neutrophils release mediators that may contribute to myocardial injury and dysfunction associated with ischemia and reperfusion. KM Mullane W Westlin R Kraemer, Ann N Y Acad Sci 1988 524 103 121
28. Role of 5-lipoxygenase in the multiple organ failure induced by zymosan. S Cuzzocrea A Rossi I Serraino R Di Paola L Dugo T Genovese D Britti G Sciarra A De Sarro AP Caputi, et al. Intensive Care Med 2004 30 10 1935 1943
29. Elucidation of the early events contributing to zymosan-induced multiple organ dysfunction syndrome using MIP-1alpha, C3 knockout, and C5-deficient mice. J Mahesh J Daly WG Cheadle GJ Kotwal, Shock 1999 12 5 340 349
30. Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARbeta/delta ligand GW0742. Z Haskova B Hoang G Luo LA Morgan AN Billin FC Barone BG Shearer ME Barton KS Kilgore, Inflamm Res 2008 57 7 314 321
31. The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. S Cuzzocrea E Mazzon R Di Paola A Peli A Bonato D Britti T Genovese C Muia C Crisafulli AP Caputi, J Leukoc Biol 2006 79 5 999
32. Peroxisome proliferator-activated receptor-alpha contributes to the anti-inflammatory activity of glucocorticoids. S Cuzzocrea S Bruscoli E Mazzon C Crisafulli V Donato R Di Paola E Velardi E Esposito G Nocentini C Riccardi, Mol Pharmacol 2008 73 2 323 337
33. Introduction to NF-kappaB: players, pathways, perspectives. TD Gilmore, Oncogene 2006 25 51 6680 6684
34. The NF-kappaB regulatory network. AR Brasier, Cardiovasc Toxicol 2006 6 2 111 130
35. Integrating cell-signalling pathways with NF-kappaB and IKK function. ND Perkins, Nat Rev Mol Cell Biol 2007 8 1 49 62
36. The Rel/NF-kappaB signal transduction pathway: introduction. TD Gilmore, Oncogene 1999 18 49 6842 6844
37. Identification of a nuclear factor kappa B-dependent gene network. B Tian AR Brasier, Recent Prog Horm Res 2003 58 95 130
38. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. BC Albensi MP Mattson, Synapse 2000 35 2 151 159
39. Improved survival of TNF-deficient mice during the zymosan-induced multiple organ dysfunction syndrome. TJ Volman T Hendriks AA Verhofstad BJ Kullberg RJ Goris, Shock 2002 17 6 468 472
40. A monoclonal antibody against tumour necrosis factor-alpha improves survival in experimental multiple organ dysfunction syndrome. MJ Jansen T Hendriks R Hermsen JW Van der Meer RJ Goris, Cytokine 1998 10 11 904 910
41. The role of E-selectin, P-selectin, and very late activation antigen-4 in T lymphocyte migration to dermal inflammation. AC Issekutz TB Issekutz, J Immunol 2002 168 4 1934 1939
42. Intercellular adhesion molecule-1 gene expression in human endothelial cells. Differential regulation by tumor necrosis factor-alpha and phorbol myristate acetate. SJ Wertheimer CL Myers RW Wallace TP Parks, J Biol Chem 1992 267 17 12030 12035
43. Multiple organ failure following zymosan-induced peritonitis is mediated by nitric oxide. S Cuzzocrea B Zingarelli L Sautebin A Rizzo C Crisafulli GM Campo G Costantino G Calapai F Nava M Di Rosa, et al. Shock 1997 8 4 268 275
44. Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects. C Szabo LH Lim S Cuzzocrea SJ Getting B Zingarelli RJ Flower AL Salzman M Perretti, J Exp Med 1997 186 7 1041 1049
45. Absence of peroxisome proliferators-activated receptors (PPAR)alpha enhanced the multiple organ failure induced by zymosan. R Di Paola E Esposito E Mazzon T Genovese C Muia C Crisafulli G Malleo E Sessa R Meli S Cuzzocrea, Shock 2006 26 5 477 484
46. Peroxynitrite-mediated DNA strand breakage activates poly-adenosine diphosphate ribosyl synthetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaccharide. B Zingarelli M O'Connor H Wong AL Salzman C Szabo, J Immunol 1996 156 1 350 358
47. Mechanisms of oxidant injury of cells. CG Cochrane, Mol Aspects Med 1991 12 2 137 147
48. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. K Sharma RX Wang LY Zhang DL Yin XY Luo JC Solomon RF Jiang K Markos W Davidson DW Scott, et al. Pharmacology & therapeutics 2000 88 3 333 347
49. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. FL Scott B Stec C Pop MK Dobaczewska JJ Lee E Monosov H Robinson GS Salvesen R Schwarzenbacher SJ Riedl, Nature 2008
50. Mitochondria and apoptosis. DR Green JC Reed, Science 1998 281 5381 1309 1312
51. Caspases: enemies within. NA Thornberry Y Lazebnik, Science 1998 281 5381 1312 1316
52. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. ZN Oltvai CL Milliman SJ Korsmeyer, Cell 1993 74 4 609 619